Literature DB >> 26621905

POEMS syndrome: complex factors contributing to a delayed diagnosis.

Rebecca Caroline Robey1, Craig Campus2, Beverly Ringuette3, Mark Shumate2.   

Abstract

POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes) syndrome is a rare paraneoplastic syndrome due to an underlying plasma cell disorder. The chronically evolving nature of this syndrome and diverse clinical manifestations make it a challenging diagnosis, especially in the early stages of the disease. We present a case that illustrates well how these confounding factors can delay recognition of the disorder. We describe the presentation of some of the classical symptoms, and discuss how investigations can be optimised in order to fit together the clinical picture. Recent advances in the understanding of nerve conduction studies and electromyography in POEMS may help improve the early identification of this disease. This is of great importance, as early recognition and the initiation of appropriate treatment can reduce morbidity and mortality in POEMS. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26621905      PMCID: PMC4680602          DOI: 10.1136/bcr-2015-213123

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome.

Authors:  Anita D'Souza; Suzanne R Hayman; Francis Buadi; Michelle Mauermann; Martha Q Lacy; Morie A Gertz; Robert A Kyle; Shaji Kumar; Philip R Greipp; John A Lust; Stephen J Russell; Steven Zeldenrust; David Dingli; Thomas E Witzig; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

2.  POEMS syndrome - a unique presentation of a rare paraneoplastic syndrome.

Authors:  J Livingston; C Cobiella; M A Hall-Craggs
Journal:  BMJ Case Rep       Date:  2010-12-01

3.  Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP.

Authors:  Michelle L Mauermann; Eric J Sorenson; Angela Dispenzieri; Jay Mandrekar; Guillermo A Suarez; Peter J Dyck; P James B Dyck
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-03-06       Impact factor: 10.154

4.  Clinical characteristics and long-term outcome of patients with POEMS syndrome in China.

Authors:  Jian Li; Dao-Bin Zhou; Zhen Huang; Li Jiao; Ming-Hui Duan; Wei Zhang; Yong-Qiang Zhao; Ti Shen
Journal:  Ann Hematol       Date:  2011-01-08       Impact factor: 3.673

5.  Different neurological and physiological profiles in POEMS syndrome and chronic inflammatory demyelinating polyneuropathy.

Authors:  Saiko Nasu; Sonoko Misawa; Yukari Sekiguchi; Kazumoto Shibuya; Kazuaki Kanai; Yumi Fujimaki; Shigeki Ohmori; Satsuki Mitsuma; Shunsuke Koga; Satoshi Kuwabara
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-02-15       Impact factor: 10.154

6.  POEMS syndrome: definitions and long-term outcome.

Authors:  Angela Dispenzieri; Robert A Kyle; Martha Q Lacy; S Vincent Rajkumar; Terry M Therneau; Dirk R Larson; Philip R Greipp; Thomas E Witzig; Rita Basu; Guillermo A Suarez; Rafael Fonseca; John A Lust; Morie A Gertz
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

Review 7.  POEMS syndrome: update on diagnosis, risk-stratification, and management.

Authors:  Angela Dispenzieri
Journal:  Am J Hematol       Date:  2015-09-01       Impact factor: 10.047

8.  Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature.

Authors:  P A Bardwick; N J Zvaifler; G N Gill; D Newman; G D Greenway; D L Resnick
Journal:  Medicine (Baltimore)       Date:  1980-07       Impact factor: 1.889

9.  An unusual case of POEMS syndrome.

Authors:  Mani Gupta; Rajesh Verma; Ravindra Kumar Garg; Maneesh Singh
Journal:  BMJ Case Rep       Date:  2012-08-24

Review 10.  New advances in the diagnosis and treatment of POEMS syndrome.

Authors:  Jian Li; Dao-bin Zhou
Journal:  Br J Haematol       Date:  2013-02-08       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.